CrashGuard: Structured Protocol & Supplement Tracker for ADHD Medication Wear-off
Users experience severe afternoon energy, mood, and cognitive crashes as Elvanse/Vyvanse wears off, with no standardized guidance or structured way to track mitigation strategies beyond chaotic trial and error.
Is the problem real?
Experiencing a harsh afternoon energy/mood crash after the initial positive effects of Elvanse (Vyvanse) wear off.
EVIDENCE
Elvanse (Vyvanse) first day
Elvanse (Vyvanse) first day
Who feels this pain?
TARGET USERS
Patients experiencing severe afternoon energy and mood crashes as daily stimulants wear off, currently relying on fragmented peer advice.
Context
Current Workarounds
Where's the gap?
EXISTING SOLUTION GAPS
OPPORTUNITY & VALUE
Clear user distress over afternoon energy crashes and reliance on fragmented trial-and-error advice.
Purpose-built specifically for stimulant wear-off management with structured tracking, rather than generic wellness or general ADHD task planners.
A lightweight web app and tracking tool that provides science-backed protocols, supplement timing schedules, and a personal tracking dashboard to log crash severity against nutrition, hydration, and supplementation.
How does it make money?
MONETIZATION
Model
Users express high frustration and distress over daily crashes ("how do I make this experience... not be so dreadful?"), making a low-cost, effective protocol well within impulse-purchase and wellness spend thresholds.
How do you ship it?
MVP PLAN
“Smooth out your afternoon ADHD medication crash in 30 days.”
A lightweight web app and tracking tool that provides science-backed protocols, supplement timing schedules, and a personal tracking dashboard to log crash severity against nutrition, hydration, and supplementation.
Core Features
Weekly Roadmap
- •Build user onboarding flow capturing medication schedule
- •Develop daily check-in interface for energy and crash intensity
- •Draft initial baseline protocol database for L-Tyrosine and hydration
- •Build correlation charts showing habit impact on crash severity
- •Implement weekly protocol adjustment recommendations
- •Add resource library with peer-vetted coping mechanisms
- •Integrate Stripe checkout for monthly subscriptions
- •Onboard 10 beta testers from ADHD online communities
- •Refine tracking UX based on beta feedback
- •Launch on r/ADHD and related support subreddits
- •Publish educational content on stimulant wear-off management
- •Track initial conversion and user retention metrics
Community-led growth targeting Reddit spaces like r/ADHD, r/vyvanse, and specialized health forums where users actively seek crash advice.
RISKS & ASSUMPTIONS
Top Risks
Providing supplement advice alongside prescription medication tracking requires strict disclaimers to avoid regulatory or health liability.
Users might solve their immediate crash issue within a few weeks and churn immediately.
Without input or review from healthcare professionals, users may hesitate to trust supplement and timing protocols.
Should you build it?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 7/10 against 2 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
Why this matters for SaaS founders
It sits at the intersection of "adhd", "consumer-app", "health", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "CrashGuard: Structured Protocol & Supplement Tracker for ADHD Medication Wear-off" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for adhd?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.